TW268943B - - Google Patents

Info

Publication number
TW268943B
TW268943B TW082108227A TW82108227A TW268943B TW 268943 B TW268943 B TW 268943B TW 082108227 A TW082108227 A TW 082108227A TW 82108227 A TW82108227 A TW 82108227A TW 268943 B TW268943 B TW 268943B
Authority
TW
Taiwan
Application number
TW082108227A
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Application granted granted Critical
Publication of TW268943B publication Critical patent/TW268943B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
TW082108227A 1992-10-07 1993-10-05 TW268943B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/957,152 US5296478A (en) 1992-10-07 1992-10-07 1-substituted oxindoles as cognition enhancers

Publications (1)

Publication Number Publication Date
TW268943B true TW268943B (zh) 1996-01-21

Family

ID=25499153

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082108227A TW268943B (zh) 1992-10-07 1993-10-05

Country Status (7)

Country Link
US (2) US5296478A (zh)
AU (1) AU5292893A (zh)
IL (1) IL107177A0 (zh)
MX (1) MX9306234A (zh)
TW (1) TW268943B (zh)
WO (1) WO1994007891A1 (zh)
ZA (1) ZA937453B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
DK0813411T3 (da) * 1995-02-15 2002-05-13 Takeda Chemical Industries Ltd Anvendelse af vincopetinderivater til hæmning af dannelse eller afsondring af amyloid -protein
HRP980429A2 (en) 1997-08-14 1999-06-30 Jianguo Yin Crystalline 10,10-bis ((2-fluoro-4-pyridinyl)methyl)-9(10h)-anthracenone and an improved process for preparing the same
US20050101929A1 (en) * 2002-01-17 2005-05-12 Andrew Waksmundzki Absorbent core with three-dimensional sub-layer
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
WO2008036282A1 (en) * 2006-09-18 2008-03-27 The Regents Of The University Of Californina Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
EP2350091B1 (en) * 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
SG10201703086VA (en) 2008-10-17 2017-05-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
RU2544852C2 (ru) * 2009-10-14 2015-03-20 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
CN106565683B (zh) * 2016-09-30 2019-03-12 江汉大学 一种合成3-羟基氧化吲哚衍生物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314954A (en) * 1964-12-09 1967-04-18 Parke Davis & Co 1-(diloweralkylamino)-3-(aminoloweralkyl)-3-phenyloxindoles
US3595866A (en) * 1970-01-19 1971-07-27 Parke Davis & Co 1-amino-3-aminoalkyl-3-phenyloxindole-compounds
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
US5173489A (en) * 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
WO1989012637A1 (en) * 1988-06-14 1989-12-28 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
ES2110965T3 (es) * 1989-07-25 1998-03-01 Taiho Pharmaceutical Co Ltd Derivado de oxoindol.
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones
US5278162A (en) * 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man

Also Published As

Publication number Publication date
MX9306234A (es) 1994-05-31
US5296478A (en) 1994-03-22
IL107177A0 (en) 1994-01-25
ZA937453B (en) 1995-04-07
WO1994007891A1 (en) 1994-04-14
US5428035A (en) 1995-06-27
AU5292893A (en) 1994-04-26

Similar Documents

Publication Publication Date Title
DE9200027U1 (zh)
TW234768B (zh)
TW268943B (zh)
TW248560B (zh)
DE9200361U1 (zh)
DE9200066U1 (zh)
DE9200192U1 (zh)
DE9210785U1 (zh)
BR9202713C1 (zh)
DE9200350U1 (zh)
DE9200083U1 (zh)
DE9203672U1 (zh)
DE9213184U1 (zh)
DE9200022U1 (zh)
DE9210487U1 (zh)
DE9200358U1 (zh)
DE9200032U1 (zh)
DE9203269U1 (zh)
DE9200035U1 (zh)
DE9210375U1 (zh)
DE9200129U1 (zh)
DE9200473U1 (zh)
DE9200130U1 (zh)
DE9200338U1 (zh)
DE9200293U1 (zh)